Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBT for GVHD Prevention
NCT02877082Phase 2Terminated
- Sponsor
- Emory University
- Start
- Sep 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in graft-versus-host disease (GVHD), sponsored by Emory University. Primary endpoints: Composite End Point of Alive and Severe Acute GVHD Free at 6 months and Safety of the Combination at 6 months. Started Sep 2016; status: terminated.
02
Drugs
bortezomib
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02877082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02877082.